Lexaria Bioscience Receives 70th Patent Award
Bitget2026/10/28 13:15- Lexaria Bioscience reached 70 patent awards with four new grants covering its DehydraTECH drug-delivery technology in the US, Canada and Europe.
- A US patent granted July 28, 2026, covers DehydraTECH processes for GLP-1 drugs to treat diabetes.
- A second US patent, granted October 13, 2026, covers DehydraTECH-processed cannabidiol for diabetes treatment.
- Canadian patent protection for DehydraTECH-processed cannabidiol to treat hypertension was granted October 20, 2026.
- European patent protection for DehydraTECH-processed cannabidiol to treat epilepsy carries an October 21, 2026, grant date.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Lithium-For-Earth Raises KRW 1.32 Billion in Private Placement
Anthropic "accidentally" leaks IPO documents! Plans to raise $69.3 billion, valuation drops from 2 trillion to 1.3 trillion
Anthropic mistakenly published and then withdrew a prospectus for a planned $69.3 billion fundraising, with its valuation dropping from a peak of $2 trillion to between $1.1 trillion and $1.3 trillion.
Subaru Publishes Transcript of First-Half FYE 2027 Financial Results Presentation
Citi: Occidental Petroleum (OXY.US) Q3 cash flow surpasses expectations, accelerated debt repayment cannot hide concerns over Q4 output
Citi published a research report maintaining Occidental Petroleum's "Neutral" rating, with a target price of $65.
Crypto prices
More
